A. O'Leary

发表

M. Lynch, A. O'Leary, 2020, Research in Social and Administrative Pharmacy.

Evaluating patient attitudes to increased patient engagement with antimicrobial stewardship: a quantitative survey

C. Bergin, A. O'Leary, G. Hughes, 2020, JAC-antimicrobial resistance.

J. Castilla, I. Martínez-Baz, A. O'Leary, 2019, Quality of Life Research.

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study

M. Barry, C. Walsh, R. Merriman, 2015, BMC Infectious Diseases.

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

K. Facey, E. Nicod, J. Espín, 2021, PharmacoEconomics.

Telementoring with project ECHO: a pilot study in Europe

Sanjeev Arora, S. Norris, C. Bergin, 2017, BMJ Innovations.

Reply to Calcagno et al.

C. Walsh, M. Barry, S. Schmitz, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bridging the gap between healthcare professions’ regulation and practice: the “lived experience” of community pharmacists in Ireland following regulatory change

N. Kodate, M. Lynch, A. O'Leary, 2022, Journal of Pharmaceutical Policy and Practice.

PanicMechanic: A Digital Therapeutic Delivering Biofeedback for Panic Attacks (Preprint)

Ellen W. McGinnis, Reed D. Gurchiek, William E. Copeland, 2021 .

NP-018 Building capacity within a Hepatitis C treatment model. The validation process for a Hepatitis C pre-treatment pharmacist assessment complex intervention toolkit

S. Norris, C. Bergin, A. O'Leary, 2021, National poster prize winners.

Potential costs and consequences associated with medication error at hospital discharge: an expert judgement study

G. Kirwan, T. Grimes, C. Walsh, 2022, European journal of hospital pharmacy : science and practice.

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

S. Simoens, S. Jan, B. Godman, 2016, Front. Pharmacol..

Baseline Prevalence and Emergence of Protease Inhibitor Resistance Mutations following Treatment in Chronic HCV Genotype-1-Infected Individuals

M. Carr, S. Norris, C. Bergin, 2015, Antiviral therapy.

Direct costs of interferon‐based and interferon‐free direct‐acting antiviral regimens for the treatment of chronic hepatitis C infection

S. Norris, A. O'Leary, E. Gray, 2016, Journal of viral hepatitis.

Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients

J. Mar, R. Adams, A. O'Leary, 2017, Expert review of gastroenterology & hepatology.

Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016

J. Castilla, I. Martínez-Baz, A. O'Leary, 2018, Postgraduate medicine.

Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?

Aisling O'Leary, Emma Gray, Susanne Schmitz, 2017, Journal of comparative effectiveness research.

Incorporating single‐arm evidence into a network meta‐analysis using aggregate level matching: Assessing the impact

Joy Leahy, Aisling O'Leary, Cathal Walsh, 2019, Statistics in medicine.

Generic substitution of antiretrovirals: patients’ and health care providers’ opinions

C. Bergin, A. O'Leary, J. Kieran, 2017, International journal of STD & AIDS.

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry

S. Norris, D. Pasta, A. O'Leary, 2017, BMC Health Services Research.

Investigation and treatment of the infertile couple

N. Amso, A. O'Leary, 2007 .

The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors

M. Carr, A. O'Leary, E. Gray, 2016, PloS one.

Determinants of HIV Outpatient Service Utilization: A Systematic Review

A. Brennan, C. Bergin, A. O'Leary, 2014, AIDS and Behavior.

Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland

M. Barry, S. Spillane, C. Usher, 2015, BMC Research Notes.

Pharmacoeconomic Evaluation in Ireland

M. Barry, L. Tilson, C. Usher, 2012, PharmacoEconomics.

The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.

M. Barry, C. Walsh, S. Schmitz, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Economic evaluation of a collaborative model of pharmaceutical care in an Irish hospital: cost-utility analysis

G. Kirwan, T. Grimes, C. Walsh, 2023, HRB open research.

Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program

J. Lambert, C. Walsh, S. Norris, 2017, Expert review of gastroenterology & hepatology.

Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort

S. Norris, C. Bergin, A. O'Leary, 2019, International Journal of Clinical Pharmacy.

High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.

J. Lambert, D. Houlihan, S. Norris, 2016, Journal of hepatology.

Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments

J. Mar, J. Castilla, I. Martínez-Baz, 2019, Expert review of gastroenterology & hepatology.

The impact of individual patient data in a network meta‐analysis: An investigation into parameter estimation and model selection

Joy Leahy, Aisling O'Leary, Nezam Afdhal, 2018, Research synthesis methods.

Telementoring with project ECHO: a pilot study in Europe

Sanjeev Arora, S. Norris, C. Bergin, 2017, BMJ Innovations.

Dapsone induced methaemoglobinaemia

C. Merry, F. Mulcahy, C. Bergin, 1996, International journal of STD & AIDS.